Omicron hammers disease-modifying drug options

Australia is fortunate to have stocks of one of the few agents maintaining efficacy, leading clinician says

The Omicron variant is undermining multiple COVID-19 treatments, although the monoclonal antibody most used in Australia is holding up well, a top immunologist says.

Professor Tony Kelleher.

A French preprint study published on bioRxiv last month found the Omicron variant was “totally or partially resistant” to nine different monoclonal antibodies being used or evaluated around the world.